Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

IL-13 Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Interleukin Related (25) Apoptosis (1) Cadherin (1) Caspase (1) STAT (2) TNF Receptor (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (26) Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Antibodies

Targets Recommended: ADC Antibody Interleukin Related IRAK Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs) ADC Linker Itk PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-126360

Oxazolone	TNF Receptor Interleukin Related	Inflammation/Immunology
Oxazolone is a haptenizing agent that induces acute or chronic inflammation of the large intestine and is used to construct models of colitis. Oxazolone can cause Th1/Th2-dependent colitis with weight loss and diarrhea. Oxazolone-induced inflammation can be mitigated by neutralizing anti-IL-4 or anti-TNF-α antibodies or decoy IL-13R2-α-FC proteins .

HY-P990093

Stapokibart CM310	Interleukin Related STAT	Inflammation/Immunology
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (K_D values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and *IL-13* with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .

HY-P991162

Tilrekimig PF-07275315	Interleukin Related	Inflammation/Immunology
Tilrekimig (PF-07275315) is a monoclonal antibody targeting human interleukin-4 (IL-4), interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). Tilrekimig can be used in the research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .

HY-P99496

Cendakimab 1 Publications Verification RPC 4046; ABT 308; CC-93538	Interleukin Related	Inflammation/Immunology
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the *IL-13* molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .

HY-P990735

Donzakimig	Interleukin Related	Inflammation/Immunology
Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G₄S)₂ linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .

HY-P99053

Tralokinumab 2 Publications Verification CAT354	Interleukin Related Apoptosis Caspase Cadherin	Inflammation/Immunology
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes *IL-13*. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .

HY-P990121

Anti-Mouse IL-4 Antibody (11B11) 1 Publications Verification	Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse IL-4 Antibody (11B11) is an anti-mouse IL-4 IgG1 monoclonal antibody. Anti-Mouse IL-4 Antibody (11B11) can inhibit Th2 cell differentiation by blocking the IL-4 signaling pathway. Anti-Mouse IL-4 Antibody (11B11) can significantly reduce fibrosis combined with anti-IL13 mAb. Anti-Mouse IL-4 Antibody (11B11) can be used for researches on cancer and inflammation conditions such as colorectal cancer and prostatitis .

HY-P990741

Galvokimig UCB-9741	Interleukin Related	Inflammation/Immunology
Galvokimig is an anti-IL13/IL17A/ALB/IL17B monoclonal antibody .

HY-P99439

Anrukinzumab IMA-638	Interleukin Related	Inflammation/Immunology
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .

HY-P990699

Riltovetbart ZTS-00008183	Interleukin Related	Inflammation/Immunology
Riltovetbart is a canine-derived IgG2 κ monoclonal antibody raised against Canlupfam *IL13* .

HY-P99883

Romilkimab SAR156597	Interleukin Related	Neurological Disease Inflammation/Immunology
Romilkimab (SAR156597) is a humanized IG antibody that specifically targets IL-4 and *IL-13*. Romilkimab can be used for the research of diffuse cutaneous systemic sclerosis .

HY-P99870

Eblasakimab ASLAN004; CSL-334; MK-6105	Interleukin Related	Others
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .

HY-P99417

Abrezekimab UCB4144; VR 942	Interleukin Related	Inflammation/Immunology
Abrezekimab (UCB4144; VR 942) is a humanized, high-affinity, neutralizing anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents IL-13 binding to the IL-13 Rα1 subunit. Abrezekimab can be used for the research of asthma .

HY-P990090

Rademikibart CBP-201	Interleukin Related STAT	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a K_D of 20.7 pM when binding to human IL-4Rα epitopes . Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and *IL-13*-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma .

HY-P991150

Ompekimig	Interleukin Related	Inflammation/Immunology
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .

HY-P991258

CNTO-5825	Interleukin Related	Inflammation/Immunology
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .

HY-P991633

TQC2938	Interleukin Related	Inflammation/Immunology
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .

HY-P99846

Dectrekumab QAX576	Interleukin Related	Inflammation/Immunology
Dectrekumab (QAX576) is a human monoclonal antibody that targets *IL-13*. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .

HY-P990442

*Anti-IL-13* Antibody (CNTO 607)** CNTO 607	Interleukin Related	Inflammation/Immunology
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed human antibody that targets *IL-13. Anti-IL-13* Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991594

*Anti-IL-13* Antibody (C836)**	Interleukin Related	Inflammation/Immunology
Anti-IL-13 Antibody (C836) is a neutralizing monoclonal antibody targeting human *IL-13. The Fab fragment of Anti-IL-13* Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .

HY-P991729

Zumilokibart APG-777	Interleukin Related	Inflammation/Immunology
Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zumilokibart can be used for the research of atopic dermatitis (AD) .

HY-P991515

TQH-2722	Interleukin Related	Inflammation/Immunology
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .

HY-P990594

GSK-679586	Interleukin Related	Inflammation/Immunology
GSK-679586 is a CHO-expressed humanized antibody that targets *IL-13*. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990602

IMA-026	Interleukin Related	Inflammation/Immunology
IMA-026 is a humanized antibody expressed in CHO cells that targets *IL-13*. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P992034

APG808 PR001	Interleukin Related	Inflammation/Immunology
APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts *IL-13* and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990093

Stapokibart CM310	Interleukin Related STAT	Inflammation/Immunology
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (K_D values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and *IL-13* with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .

HY-P991162

Tilrekimig PF-07275315	Interleukin Related	Inflammation/Immunology
Tilrekimig (PF-07275315) is a monoclonal antibody targeting human interleukin-4 (IL-4), interleukin-13 (IL-13) and thymic stromal lymphopoietin (TSLP). Tilrekimig can be used in the research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .

HY-P99496

Cendakimab 1 Publications Verification RPC 4046; ABT 308; CC-93538	Interleukin Related	Inflammation/Immunology
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the *IL-13* molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .

HY-P990735

Donzakimig	Interleukin Related	Inflammation/Immunology
Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G₄S)₂ linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .

HY-P99053

Tralokinumab 2 Publications Verification CAT354	Interleukin Related Apoptosis Caspase Cadherin	Inflammation/Immunology
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes *IL-13*. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .

HY-P990121

Anti-Mouse IL-4 Antibody (11B11) 1 Publications Verification	Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse IL-4 Antibody (11B11) is an anti-mouse IL-4 IgG1 monoclonal antibody. Anti-Mouse IL-4 Antibody (11B11) can inhibit Th2 cell differentiation by blocking the IL-4 signaling pathway. Anti-Mouse IL-4 Antibody (11B11) can significantly reduce fibrosis combined with anti-IL13 mAb. Anti-Mouse IL-4 Antibody (11B11) can be used for researches on cancer and inflammation conditions such as colorectal cancer and prostatitis .

HY-P990741

Galvokimig UCB-9741	Interleukin Related	Inflammation/Immunology
Galvokimig is an anti-IL13/IL17A/ALB/IL17B monoclonal antibody .

HY-P99439

Anrukinzumab IMA-638	Interleukin Related	Inflammation/Immunology
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .

HY-P990699

Riltovetbart ZTS-00008183	Interleukin Related	Inflammation/Immunology
Riltovetbart is a canine-derived IgG2 κ monoclonal antibody raised against Canlupfam *IL13* .

HY-P99883

Romilkimab SAR156597	Interleukin Related	Neurological Disease Inflammation/Immunology
Romilkimab (SAR156597) is a humanized IG antibody that specifically targets IL-4 and *IL-13*. Romilkimab can be used for the research of diffuse cutaneous systemic sclerosis .

HY-P99870

Eblasakimab ASLAN004; CSL-334; MK-6105	Interleukin Related	Others
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .

HY-P99417

Abrezekimab UCB4144; VR 942	Interleukin Related	Inflammation/Immunology
Abrezekimab (UCB4144; VR 942) is a humanized, high-affinity, neutralizing anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents IL-13 binding to the IL-13 Rα1 subunit. Abrezekimab can be used for the research of asthma .

HY-P990090

Rademikibart CBP-201	Interleukin Related STAT	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a K_D of 20.7 pM when binding to human IL-4Rα epitopes . Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and *IL-13*-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma .

HY-P991150

Ompekimig	Interleukin Related	Inflammation/Immunology
Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). Ompekimig is promising for research of immune-mediated inflammatory diseases, such as asthma and atopic dermatitis .

HY-P991258

CNTO-5825	Interleukin Related	Inflammation/Immunology
CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .

HY-P991633

TQC2938	Interleukin Related	Inflammation/Immunology
TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research .

HY-P99846

Dectrekumab QAX576	Interleukin Related	Inflammation/Immunology
Dectrekumab (QAX576) is a human monoclonal antibody that targets *IL-13*. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .

HY-P990442

*Anti-IL-13* Antibody (CNTO 607)** CNTO 607	Interleukin Related	Inflammation/Immunology
Anti-IL-13 Antibody (CNTO 607) is a CHO-expressed human antibody that targets *IL-13. Anti-IL-13* Antibody (CNTO 607) features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-13 Antibody (CNTO 607) can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991594

*Anti-IL-13* Antibody (C836)**	Interleukin Related	Inflammation/Immunology
Anti-IL-13 Antibody (C836) is a neutralizing monoclonal antibody targeting human *IL-13. The Fab fragment of Anti-IL-13* Antibody (C836) is a heterodimer composed of heavy chains and light chains, each folded into variable and constant domains. Anti-IL-13 Antibody (C836) can be used for chronic inflammatory diseases, such as asthma .

HY-P991729

Zumilokibart APG-777	Interleukin Related	Inflammation/Immunology
Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zumilokibart can be used for the research of atopic dermatitis (AD) .

HY-P991515

TQH-2722	Interleukin Related	Inflammation/Immunology
TQH-2722 is a humanized IgG4 anti-IL-4Rα monoclonal antibody. TQH-2722 targets the IL-4Rα receptor in humans, effectively disrupting the interaction between IL-4Rα and the downstream cytokines IL-4 and IL-13, thereby inhibiting inflammatory response. TQH-2722 can be used for the study of atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) .

HY-P990594

GSK-679586	Interleukin Related	Inflammation/Immunology
GSK-679586 is a CHO-expressed humanized antibody that targets *IL-13*. GSK-679586 is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for GSK-679586 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990602

IMA-026	Interleukin Related	Inflammation/Immunology
IMA-026 is a humanized antibody expressed in CHO cells that targets *IL-13*. IMA-026 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.88 kDa. The isotype control for IMA-026 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990444

*Anti-IL-13* Antibody (M1295)** M1295	Inhibitory Antibodies	Inflammation/Immunology
The Anti-IL-13 Antibody (M1295) is a human-derived antibody expressed in CHO, targeting *IL-13. Anti-IL-13* Antibody (M1295) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-IL-13 Antibody (M1295) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990443

*Anti-IL-13* Antibody (H2L6)** H2L6	Inhibitory Antibodies	Inflammation/Immunology
Anti-IL-13 Antibody (H2L6) is a humanized antibody expressed in CHO cells that targets *IL-13. Anti-IL-13* Antibody (H2L6) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.16 kDa. The isotype control for Anti-IL-13 Antibody (H2L6) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P992034

APG808 PR001	Interleukin Related	Inflammation/Immunology
APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts *IL-13* and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis .

Host:	Rat (1) Mouse (4) Rabbit (2)
Reactivity:	Human (4) mouse (1) human (2)
Application:	ICC/IF (1) IF-Tissue (1) IP (3) WB (6) FC (3) ELISA (5)
Isotype:	IgG (2) IgG1 (5)
Conjugation:	Non-conjugated (7)
Clonality:	Monoclonal (3) Recombinant (2)
Modification:	Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P810105

	IL-13 Antibody (YA9449)	WB, ICC/IF, IF-Tissue, IP, ELISA	mouse
	IL-13 Antibody (YA9449) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IL-13.

HY-P810262

	IL-13 Antibody (YA9606)	WB, IP, ELISA	human
	IL-13 Antibody (YA9606) is a Rat-derived and non-conjugated IgG1 monoclonal antibody, targeting to IL-13.

HY-P84441

	IL-13 Receptor alpha 1 Antibody (YA4138) IL13RA1; NR4; CT19; IL-13Ra	WB, FC, ELISA	Human
	IL-13 Receptor alpha 1 Antibody (YA4138) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IL-13 Receptor alpha 1.

HY-P84441A

	IL-13 Receptor alpha 1 Antibody (YA4138)(PBS only) IL13RA1; NR4; CT19; IL-13Ra	WB, FC, ELISA	Human
	IL-13 Receptor alpha 1 Antibody (YA4138) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IL-13 Receptor alpha 1.

HY-P81879

	IL-13 Receptor alpha 1 Antibody (YA1624) IL13RA1; IL13R; IL13RA; Interleukin-13 receptor subunit alpha-1; IL-13 receptor subunit alpha-1; IL-13R subunit alpha-1; IL-13R-alpha-1; IL-13RA1; Cancer/testis antigen 19; CT19; CD antigen CD213a1	WB	Human
	IL-13 Receptor alpha 1 Antibody (YA1624) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IL-13 Receptor alpha 1.

HY-P81632

	IL-13 Receptor alpha 1 Antibody (YA1377) IL13RA1; IL13R; IL13RA; Interleukin-13 receptor subunit alpha-1; IL-13 receptor subunit alpha-1; IL-13R subunit alpha-1; IL-13R-alpha-1; IL-13RA1; Cancer/testis antigen 19; CT19; CD antigen CD213a1	FC, ELISA	Human
	IL-13 Receptor alpha 1 Antibody (YA1377) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to IL-13 Receptor alpha 1.

HY-P89707

	IL-13Rα2 Antibody (YA9051) CD213a2, IL13R, IL13RA2, Interleukin-13 receptor subunit alpha-2, IL-13 receptor subunit alpha-2, IL-13R subunit alpha-2, IL-13R-alpha-2, IL-13RA2, Interleukin-13-binding protein	WB, IP	human
	IL-13Rα2 Antibody (YA9051) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to IL-13Rα2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: